NCT06926075View on ClinicalTrials.gov

Early Phase Study of Kesonotide in Participants With Solid Tumours

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

October 26, 2027

Study Completion Date

October 26, 2027

Conditions
Prostate CancersBreast CancerLung CancersOvarian CancerGlioblastoma Multiforme (GBM)Pancreas CancerSkin Cancer
Interventions
DRUG

A novel hGIIA-Vimentin Inhibitor

Phase I, dose escalation includes 4 increasing doses, 10mg, 30mg, 60mg and 120mg.

DRUG

Dose expansion

Phase II will enrol participants in selected indication(s) and will be given one of the two recommended doses by the SMC.

Sponsors

Lead Sponsor

Filamon LTD
All Listed Sponsors
lead

Filamon LTD

INDUSTRY